Liraglutide: Side Effects & Safety

Liraglutide has more real-world safety data than any other GLP-1 agonist on this site. It was FDA-approved as Victoza for type 2 diabetes in 2010 and as Saxenda for chronic weight management in 2014. The LEADER cardiovascular outcomes trial enrolled 9,340 patients with type 2 diabetes followed for a median 3.8 years.^[1] The SCALE obesity trial enrolled 3,731 patients followed for 56 weeks.^[2] Combined with over a decade of post-marketing surveillance, this is one of the best-characterized peptide safety profiles in clinical medicine.

The class warnings — pancreatitis, thyroid C-cell tumors, gallbladder events — are well-known and on every GLP-1 agonist label. The bigger practical issue for most patients is GI tolerability during dose titration.

Liraglutide is not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda — it does not need to be, because it is FDA-approved as Saxenda / Victoza. Compounded liraglutide is also available through licensed pharmacies.

Pooled from the SCALE obesity trial program, active arm vs placebo.^[2]

Effect	Saxenda 3.0 mg	Placebo	Notes
Nausea	39.3%	13.8%	Peaks during titration; declines with stable dosing
Diarrhea	20.9%	9.9%	Usually mild-moderate
Constipation	19.4%	8.5%	From slowed gastric motility
Vomiting	15.7%	3.9%	Dose-related
Hypoglycemia (non-diabetic patients, monotherapy)	1.6%	1.1%	Generally low risk; rises sharply when combined with insulin / sulfonylureas in diabetic patients
Headache	13.6%	12.6%	Often transient
Decreased appetite	10.0%	1.4%	Pharmacological effect, not adverse
Fatigue	7.5%	4.6%	Often related to caloric restriction
Injection-site reactions	13.9%	10.5%	Mild, transient
Cholelithiasis (gallstones)	2.5%	1.0%	Likely secondary to rapid weight loss
Acute pancreatitis	0.4%	0.5%	LEADER trial — not increased vs placebo, but on the class label warning
Discontinuation due to adverse events	9.8%	4.3%	Mostly GI-driven

The FDA Saxenda and Victoza labels carry a boxed warning for thyroid C-cell tumors based on rodent toxicology studies — long-duration GLP-1R agonist exposure in rats and mice produces dose-dependent C-cell hyperplasia and medullary thyroid carcinoma.^[3]

Human relevance is uncertain. Rodent thyroid C-cells express dramatically more GLP-1 receptors than human C-cells, and over a decade of clinical use has not produced an MTC signal in humans. The boxed warning remains because:

• Medullary thyroid carcinoma is rare in the general population, so detecting a small relative increase requires very large datasets and long follow-up.
• The rodent data is strong enough that the FDA cannot rule out a human risk.

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia type 2 (MEN 2).

If you have a family history of "thyroid cancer," clarify the type — only MTC is the contraindication, not the much more common papillary or follicular thyroid cancers.

Acute pancreatitis

Class warning across all GLP-1 agonists. Rate in LEADER was 0.4% liraglutide vs 0.5% placebo over 3.8 years — not increased, but the FDA label still warns to monitor.

• Symptoms: persistent severe abdominal pain, often radiating to the back, often with nausea/vomiting.
• If suspected: stop liraglutide immediately and seek evaluation (serum lipase, imaging).
• If confirmed: do not restart liraglutide. Switch to a non-GLP-1 therapy.
• Contraindicated in patients with history of pancreatitis (relative contraindication).

Gallbladder events

Saxenda increased cholelithiasis (gallstones) by approximately 2.5× vs placebo in SCALE. The mechanism is likely rapid weight loss rather than direct drug effect — gallstones are a known risk of any rapid weight loss intervention.

• Symptoms: right upper quadrant pain, especially after fatty meals; jaundice.
• If suspected: ultrasound evaluation. May require cholecystectomy if symptomatic.

• Personal or family history of medullary thyroid carcinoma or MEN 2: boxed warning, absolute contraindication.
• Type 1 diabetes: not approved; not for primary glucose management.
• Pregnancy: Category X. Discontinue at least 2 months before planned conception.
• Breastfeeding: not recommended; excretion into human milk uncharacterized.
• History of pancreatitis: relative contraindication.
• Severe gastrointestinal disease (gastroparesis, IBD active flare, severe motility disorders): avoid.
• Severe hepatic or renal impairment: use with caution; reduced data.
• Active diabetic proliferative retinopathy: rapid HbA1c reduction has been linked to retinopathy progression (more documented for semaglutide in SUSTAIN-6, plausible class effect).
• Active gallbladder disease: increased gallstone risk.
• Suicidal ideation or recent suicide attempt: precautionary — GLP-1 class drugs are under post-market surveillance for psychiatric adverse events.
• Known hypersensitivity to liraglutide or formulation excipients.

Drug interactions

• Insulin / sulfonylureas: hypoglycemia risk. Reduce dose.
• Oral medications (oral contraceptives, levothyroxine, warfarin, narrow-therapeutic-index drugs): delayed gastric emptying alters absorption. Monitor.
• Other GLP-1 agonists (semaglutide, tirzepatide, dulaglutide, exenatide): do not combine. Switch directly.
• DPP-4 inhibitors (sitagliptin, saxagliptin): not contraindicated but redundant in mechanism. Generally discontinue DPP-4 inhibitor when starting GLP-1 agonist.
• Alcohol: increases hypoglycemia risk in diabetic patients on insulin/sulfonylureas.

• Mild GI symptoms during titration: hold at current dose for an extra week before next escalation step. Eat smaller meals, avoid high-fat foods, hydrate.
• Severe persistent abdominal pain: stop and seek evaluation for pancreatitis.
• Right upper quadrant pain, jaundice: evaluate for gallbladder disease.
• Neck mass, hoarseness, persistent cough, swallowing difficulty: immediate evaluation for thyroid C-cell pathology.
• Vision changes (diabetic patients): ophthalmology evaluation for retinopathy progression.
• Hypoglycemic symptoms (in diabetic patients): reduce insulin/sulfonylurea dose; have fast-acting carbohydrate available.
• New mood symptoms or suicidal ideation: contact your prescriber immediately. Crisis line: 988 (US Suicide & Crisis Lifeline).
• Allergic reaction (rash, hives, breathing difficulty): discontinue immediately and seek emergency care.

See the liraglutide complete guide, dosage protocols, semaglutide vs liraglutide comparison, and the complete GLP-1 guide.